LIFESTANCE HLTH.GRP -,01 Aktie

Lifestance Health Group reported quarterly revenue growth of 26% and a 94% increase in adjusted EBITDA at the Jefferies Healthcare Services and Technology Conference. Management highlighted an upward revision of the full-year revenue guide by $45 million and the adjusted EBITDA guide by $15 million, and sees an addressable therapy market of more than $50 billion. The company plans a phased rollout of its own EHR platform through 2027, expects mid‑teens revenue growth in the medium term, and targets adjusted EBITDA margins in the mid‑teens by 2028; specialized services and a national hybrid footprint are expected to drive further growth and margin expansion. » Mais em de.investing.com

Lifestance Health Group shares fall about 3.9% in premarket trading after the announcement that existing shareholders intend to sell 22,250,000 shares in a secondary placement. Barclays is acting as sole underwriter; LifeStance itself is issuing no new shares and will receive no proceeds from the transaction. The company also approved a conditional buyback of 2,000,000 shares at the same price as the underwriter, but the buyback is contingent on the placement closing. The combination of the large sell volume and a weak overall market pushes the price down to $12.30 and intensifies the negative market reaction. » Mais em de.investing.com

LifeStance has set the price for a secondary placement of 22,250,000 common shares at $12.35 per share. The company itself is not selling any shares and will receive no proceeds; the proceeds will go to the selling shareholders. LifeStance may optionally purchase 2,000,000 shares from the underwriter at the same price; closing of the transaction is expected on September 11, 2026, and Barclays is acting as underwriter. » Mais em de.investing.com

Lifestance Health Group’s stock rose to a 52‑week high of $12.97 and trades around $13, implying a market cap of about $4.81 billion and a 129.51% gain over the past year. For Q2 2026 the company reported adjusted EPS of $0.06 and revenue of $435.35 million, both above analyst expectations, and raised its full‑year guidance. 26% revenue growth, an increase in adjusted EBITDA margin to 15.2% and 2.6 million visits (+19%) contributed to the positive reaction, while an InvestingPro analysis still rates the stock as slightly overvalued despite a low PEG of 0.23. » Mais em de.investing.com

Lifestance Health’s stock rose to a 52-week high of 11.77 USD (current price 11.78 USD), giving it a market capitalization of 4.35 billion USD. InvestingPro rates the stock as slightly overvalued despite a 148% price gain over the past year. Operationally, LifeStance reported strong Q2 results: adjusted EPS of 0.06 USD (expected 0.03 USD), revenue of 435.35 million USD (+26% year-on-year) and adjusted EBITDA of 66 million USD (+94%), after which the full-year guidance was raised. » Mais em de.investing.com